Is rituximab therapy a risk factor for development of melanoma?
dermoscopy
nevus
rituximab
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
25
03
2020
revised:
13
04
2020
accepted:
23
04
2020
pubmed:
30
4
2020
medline:
15
5
2021
entrez:
30
4
2020
Statut:
ppublish
Résumé
In the literature, there are reports about dermoscopic and size changes of nevi in patients undergoing biologic therapy and chemotherapeutics. There has not been any established data for melanoma and Rituximab therapy. Sixteen patients, with 94 nevi were included in this study. Dermoscopic images of follow-up visits, which were performed at baseline, 3, 6, and 12 months after treatment, were evaluated. Suspicious lesions were excised. There was no increase in total nevus count. Although 61.7% of the 94 nevi have shown a stable duration without size changes, 26.5% had enlarged, and 11.7% had become smaller during our 1-year experience of dermoscopic monitoring. There was not any pattern transformation. Atypical dots and clods appeared in 17% of nevi. All of the excised nevi were comparable with Clark nevi, there was no clue for melanoma development. According to our results, we found that Rituximab therapy influences nevus morphology, but there is no evidence that this was linked to melanoma development.
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13471Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Koseoglu G, Akay BN, Kucuksahin O, Erdem C. Dermoscopic changes in melanocytic nevi in patients receiving immunosuppressive and biologic treatments: results of a prospective case-control study. J Am Acad Dermatol. 2015;73(4):623-629.
Argenziano G, Fabbrocini G, Carli P, De Giorgi V, Sammarco E, Delfino M. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol. 1998;134(12):1563-1570.
Luther H, Altmeyer P, Garbe C, et al. Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. Arch Dermatol. 1996;132:1473-1478.
Siskind V, Darlington S, Green L, Green A. Evolution of melanocytic nevi on the faces and necks of adolescents: a 4 y longitudinal study. J Invest Dermatol. 2002;118:500-504.
Hutchinson J. Outbreak of a large crop of moles. Remarks as to possible connection with melanosis. J Cutan Med Dis Skin. 1868;1:170-171.
Melo JN, Teruya PY, Machado MC, et al. Epidermolysis bullosa nevi: clinical, dermatoscopical and histological features in a case of recessive dystrofic form. An Bras Dermatol. 2011;86(4):743.
Bovenschen HJ, Tijoe M, Vermaat H. Induction of eruptive benign melanocytic nevi by immune suppressive agents, including biologics. Br J Dermatol. 2006;154(5):880-884.
Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14:455-467.
Perier-Muzet M, Boespflug A, Poulalhon N, et al. Dermoscopic evaluation of melanocytic nevi changes with combined mitogen-activated protein kinase pathway inhibitors therapy for melanoma. JAMA Dermatol. 2016;152(10):1162-1164.
Yamamura K, Otsuka A, Kaku Y, et al. Dermoscopic changes in malignant melanoma after successful treatment with nivolumab: a case report. J Dermatol. 2017;44(5):547-548.